Medicare Enrolled

Dr. Uzma Syeda, MD

Rheumatology · Grapevine, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1501 W NORTHWEST HWY, Grapevine, TX 76051
8174167695
In practice since 2006 (19 years)
NPI: 1174562565 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Syeda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Syeda? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Syeda

Dr. Uzma Syeda is a rheumatology in Grapevine, TX, with 19 years in practice. Based on federal Medicare data, Dr. Syeda performed 53,205 Medicare services across 591 unique beneficiaries.

Between the years covered by Open Payments, Dr. Syeda received a total of $9,063 from 42 pharmaceutical and/or device companies across 471 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Syeda is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 22% volume in TX$ $9,063 industry payments

Medicare Practice Summary

Medicare Utilization ↗
53,205
Medicare services
Top 22% in TX for rheumatology
591
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,800 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)49,600$4$16
Denosumab injection (Prolia/Xgeva)2,100$18$70
Office visit, established patient (30-39 min)653$91$376
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle362$58$262
Administration of chemotherapy into vein, 1 hour or less148$104$472
Injection, zoledronic acid, 1 mg120$6$34
Steroid injection (triamcinolone)88$1$27
New patient office visit (45-59 min)66$127$368
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less24$49$233
New patient office visit, complex (60-74 min)22$175$418
Office visit, established patient, complex (40-54 min)22$120$418
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$9,063
Total received (2018-2024)
Avg $1,295/year across 7 years
Top 34% in TX for rheumatology
42
Companies
471
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,917 (98.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$145 (1.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,518
2023
$1,967
2022
$1,720
2021
$1,113
2020
$509
2019
$1,106
2018
$1,130

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,998
Janssen Biotech, Inc.
$763
GlaxoSmithKline, LLC.
$653
AbbVie Inc.
$598
ABBVIE INC.
$558
UCB, Inc.
$555
Novartis Pharmaceuticals Corporation
$526
AbbVie, Inc.
$488
Lilly USA, LLC
$468
E.R. Squibb & Sons, L.L.C.
$465
PFIZER INC.
$193
Horizon Therapeutics plc
$174
AstraZeneca Pharmaceuticals LP
$163
West-Ward Pharmaceuticals
$145
Aurinia Pharma U.S., Inc.
$127
Radius Health, Inc.
$109
Boehringer Ingelheim Pharmaceuticals, Inc.
$107
MEDEXUS PHARMA, INC.
$90
ANI Pharmaceuticals, Inc.
$68
Mallinckrodt LLC
$65
Organon Llc
$63
Assertio Therapeutics, Inc.
$55
GENZYME CORPORATION
$53
Antares Pharma, Inc.
$49
Alexion Pharmaceuticals, Inc.
$48
Organon LLC
$48
Celltrion USA Inc.
$42
Genentech USA, Inc.
$42
Fresenius Kabi USA, LLC
$40
Takeda Pharmaceuticals U.S.A., Inc.
$36
Almatica Pharma LLC
$36
Octapharma USA, Inc.
$32
Kiniksa Pharmaceuticals International, plc
$27
Teva Pharmaceuticals USA, Inc.
$27
Merck Sharp & Dohme Corporation
$25
Medtronic, Inc.
$23
Mylan Institutional Inc.
$21
SCILEX PHARMACEUTICALS INC.
$19
Mallinckrodt Hospital Products Inc.
$17
Hikma Pharmaceuticals USA
$16
Integra LifeSciences Corporation
$15
Horizon Pharma plc
$14
Top 3 companies account for 37.7% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Arcalyst · BENLYSTA · BILAYER WOUND MATRIX (BWM) · Bimzelx · COSENTYX · CYLTEZO · Cimzia · EVENITY · EVUSHELD · Enbrel · GRALISE · Gralise · HADLIMA · HUMIRA · Humira · IDACIO · INTELLIS ADAPTIVESTIM · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · Mitigare · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TREMFYA · Truxima · Tymlos · Uloric · XELJANZ · YUFLYMA · ZTLido · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $17 per 100 Medicare services performed
Looking for a rheumatology in Grapevine?
Compare rheumatologys in the Grapevine area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
98
Per 100K population
4.6
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Syeda is a mixed practice specialist, with above-average Medicare volume (top 22% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Syeda experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Syeda performed 49,600 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Syeda receive payments from pharmaceutical companies?
Yes. Dr. Syeda received a total of $9,063 from 42 companies across 471 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Syeda's costs compare to other rheumatologys in Grapevine?
Dr. Syeda's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Syeda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →